Contact Us Site Map

Main menu

Skip to content
  • Home
  • Glossary
  • Site Map
  • Terms of Use
  • About Us
    • Overview
    • Historical Timeline
    • Executive Team
    • Board of Directors
    • Corporate Responsibility
      • Corporate Giving and Grants
        • Grant Guidelines
        • Submit a Grant Request
      • Prescriber Data Privacy
      • Code of Conduct
      • Compliance Reporting
      • Corporate Compliance
    • Corporate Values
    • Partnering with Onyx
      • Partnerships
    • Awards and Recognitions
    • Contact Us
  • Therapies
    • Overview
    • Nexavar® for Advanced Kidney Cancer
      • About Kidney Cancer
      • Resources
    • Nexavar® for Unresectable Liver Cancer
      • About Liver Cancer
      • Resources
    • Patient Access
  • Clinical Development
    • Overview
    • Clinical Pipeline
    • Sorafenib
      • Kidney Cancer
      • Liver Cancer
      • Lung Cancer
      • Thyroid Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Ovarian Cancer
    • Carfilzomib
      • Expanded Access Program
      • Multiple Myeloma
      • Solid Tumors
    • ONX 0912
      • Solid Tumors
    • ONX 0914
    • Cell Cycle Kinase Inhibitor
  • Investors
    • Overview
    • Event Calendar
    • Analyst Coverage
    • SEC Filings
    • Financial Information
    • Stock Information
    • Annual Report
    • Proxy Materials
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Code of Conduct
      • Trading Policy
    • Litigation Update
    • Information Request
  • News & Media
    • Overview
    • Press Releases
      • Current Press Releases
      • 2010 Press Releases
      • 2009 Press Releases
      • 2008 Press Releases
      • 2007 Press Releases
      • 2006 Press Releases
    • Online Media Kit
  • Careers
    • Overview
    • Job Openings
    • Benefits
    • How to Apply

News

17 Jan 2012
Phase 3 Data Show Bayer’s Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approval Therapies

3 Jan 2012
Onyx Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference

14 Dec 2011
Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals Announce Multi-Year Collaboration to Accelerate Personalized Medicine Approaches for Multiple Myeloma

12 Dec 2011
Onyx Pharmaceuticals Presents Carfilzomib Data at 53rd American Society of Hematology Annual Meeting

Events

ARCHIVED EVENTS:

    9 Jan 2012

    30th Annual J.P. Morgan Healthcare Conference

UPCOMING EVENTS:

    27 Feb 2012

    Citi 2012 Global Healthcare Conference

    13 Mar 2012

    Barclays Capital Global Healthcare Conference

Spotlight

N. Anthony Coles, M.D., President and CEO of Onyx is featured as a guest columnist for the Alexandria Oncology Summit website. In the editorial, Dr. Coles discusses the importance of academic and industry partnerships to translate innovation into new approaches for cancer therapeutics and diagnostics.

Carfilzomib – In Development

The Carfilzomib Myeloma Access Program (C-MAP) makes carfilzomib available to eligible patients in the United States with relapsed and refractory multiple myeloma. Carfilzomib is being developed as a treatment for multiple myeloma and is being studied in select solid tumors.

Nexavar

Nexavar® (sorafenib) tablets, is approved in more than 100 countries for the treatment for patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, and for patients with advanced renal cell carcinoma (RCC), or kidney cancer.

Learn more about Nexavar

© Onyx 2012  Terms of Use

  • Home
  • About Us
  • Therapies
  • Clinical Development
  • Investors
  • News & Media
  • Careers
  • Glossary